I am a
Home I AM A Search Login

Papers of the Week

2022 May 14

Br J Cancer

A first-in-human Phase I dose-escalation trial of the novel therapeutic peptide, ALM201, demonstrates a favourable safety profile in unselected patients with ovarian cancer and other advanced solid tumours.


El Helali A, Plummer R, Jayson GC, Coyle VM, Drew Y, Mescallado N, Harris N, Clamp AR, McCann J, Swaisland H, Kennedy RD, Cranston AN, Wilson RH
Br J Cancer. 2022 May 14.
PMID: 35568736.


We aimed to assess the safety, tolerability and pharmacokinetics of a novel anti-angiogenic peptide.